F182112 vs Teclistamab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA x CD3 · full Multiple Myeloma pipeline

F182112

Developed by Shandong New Time Pharmaceutical Co., Ltd.

Phase 3 in Multiple Myelomabispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2027 · NCT07828522 (registry estimate)

No aligned efficacy figure on record for this race.

Teclistamab

Marketed by Johnson & Johnson

Approved in Multiple Myelomabispecific antibody (T-cell engager)
Partial signal

NCT05083169 · Phase 3 · active, not recruiting

MajesTEC-3 was a randomized, open-label Phase 3 comparing teclistamab plus daratumumab with daratumumab-based standard regimens (DPd or DVd) in relapsed multiple myeloma. Its primary endpoint, progression-free survival, is a clinical outcome and was met. An open-label trial is never graded strong under the rubric.

Next expected readout: November 2026 · NCT06505369 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (Up to 5 years): Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16). (met)

Result source: NCT05083169

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointF182112Teclistamab
PFS, median—Trial running · NCT07579234—Trial running · NCT07887984
OS, median—Trial running · NCT07579234—Trial running · NCT07887984
ORR—Trial running · NCT07579234—Trial running · NCT07887984
VGPR or better—Trial running · NCT07579234—Trial running · NCT07887984
MRD negativity—Trial running · NCT07579234—Trial running · NCT07887984

PFS, median

F182112
—Trial running · NCT07579234
Teclistamab
—Trial running · NCT07887984

OS, median

F182112
—Trial running · NCT07579234
Teclistamab
—Trial running · NCT07887984

ORR

F182112
—Trial running · NCT07579234
Teclistamab
—Trial running · NCT07887984

VGPR or better

F182112
—Trial running · NCT07579234
Teclistamab
—Trial running · NCT07887984

MRD negativity

F182112
—Trial running · NCT07579234
Teclistamab
—Trial running · NCT07887984
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

F182112: no structured comparison results are available for Multiple Myeloma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Teclistamab
Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16). NCT05083169 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months NCT04696809 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: F182112's landscape · Teclistamab's landscape